We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GDX icon
101
VanEck Gold Miners ETF
GDX
$21.8B
$1.36M 0.03%
26,200
– –
RYTM icon
102
Rhythm Pharmaceuticals
RYTM
$7.31B
$1.32M 0.03%
20,906
+5,356
+34% +$328K
PTGX icon
103
Protagonist Therapeutics
PTGX
$9.06B
$1.08M 0.02%
19,472
+1,850
+10% +$88.8K
BBNX
104
Beta Bionics
BBNX
$770M
$973K 0.02%
66,825
– –
CERT icon
105
Certara
CERT
$1.08B
$956K 0.02%
81,740
– –
SMMT icon
106
Summit Therapeutics
SMMT
$10.7B
$888K 0.02%
41,738
-25,947
-38% -$592K
IWM icon
107
iShares Russell 2000 ETF
IWM
$81.7B
$496K 0.01%
2,300
– –
BBIO icon
108
BridgeBio Pharma
BBIO
$15.9B
$449K 0.01%
10,400
– –
NVO
109
Novo Nordisk
NVO
$223B
$449K 0.01%
+6,500
New +$442K
MRUS
110
DELISTED
Merus
MRUS
$408K 0.01%
7,765
-235
-3% -$11K
EXEL icon
111
Exelixis
EXEL
$14.1B
$375K 0.01%
8,500
– –
NAMS icon
112
NewAmsterdam Pharma
NAMS
$3.7B
$372K 0.01%
20,555
-1,245
-6% -$22.7K
ARQT icon
113
Arcutis Biotherapeutics
ARQT
$3.56B
$337K 0.01%
24,008
-11,692
-33% -$164K
MDGL icon
114
Madrigal Pharmaceuticals
MDGL
$12.8B
$333K 0.01%
1,100
– –
ADMA icon
115
ADMA Biologics
ADMA
$2.02B
$308K 0.01%
16,900
– –
PLNT icon
116
Planet Fitness
PLNT
$4.14B
$294K 0.01%
+2,700
New +$270K
QURE icon
117
uniQure
QURE
$2.77B
$273K 0.01%
19,610
-2,890
-13% -$38.9K
TVTX icon
118
Travere Therapeutics
TVTX
$5.27B
$271K 0.01%
18,303
-4,797
-21% -$79.5K
CAI
119
Caris Life Sciences
CAI
$4.66B
$267K 0.01%
+10,000
New +$270K
GOOGL icon
120
Alphabet (Google) Class A
GOOGL
$4.23T
$256K 0.01%
1,450
+350
+32% +$57.3K
AMZN icon
121
Amazon
AMZN
$2.66T
$252K 0.01%
1,150
+250
+28% +$49.5K
MTSR
122
DELISTED
Metsera Inc
MTSR
$222K ﹤0.01%
+7,800
New +$194K
MLYS icon
123
Mineralys Therapeutics
MLYS
$2.39B
$210K ﹤0.01%
15,556
-943
-6% -$13.7K
BRBR icon
124
BellRing Brands
BRBR
$1.41B
$203K ﹤0.01%
3,500
+2,100
+150% +$140K
ACLX
125
DELISTED
Arcellx
ACLX
$198K ﹤0.01%
3,000
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.